Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.40 |
| ▸ | WDR5 | P61964 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26406990 | 1.00 | HSD11B1 (0.40) | HSD11B1WDR5ALDH1A1LMNATRPV1 | |
| SCHEMBL17708166 | 0.84 | LMNA (0.39) | HSD11B1ALDH1A1LMNANOTUM | |
| SCHEMBL25678510 | 0.84 | HTR2C (0.40) | HSD11B1ALDH1A1LMNATRPV1NOTUM | |
| SCHEMBL24123784 | 0.83 | TRPV1 (0.35) | HSD11B1ALDH1A1TRPV1 | |
| SCHEMBL25678498 | 0.83 | TRPV1 (0.35) | HSD11B1ALDH1A1TRPV1 | |
| SCHEMBL20180600 | 0.82 | WDR5 (0.41) | HSD11B1WDR5NOTUMHTR1DHTR1B | |
| SCHEMBL25675666 | 0.81 | RECQL (0.39) | HSD11B1WDR5ALDH1A1LMNATRPV1 | |
| SCHEMBL16541456 | 0.81 | TP53 (0.44) | HSD11B1WDR5ALDH1A1NOTUMHTR1D | |
| SCHEMBL12139619 | 0.79 | ASIC3 (0.51) | HSD11B1ALDH1A1 | |
| SCHEMBL17708167 | 0.78 | CYP1A2 (0.43) | HSD11B1ALDH1A1LMNANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4169919-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021254389-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | WEE1, WEE2, PEAK1 | HSD11B1 789/4885WDR5 255/4885ALDH1A1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.